Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis

Experimental Cell Research

Volumn 293, Issue 2, 2004, Pages 311-320

  Di Stefano, Valeria ^a   Rinaldo, Cinzia ^a   Sacchi, Ada ^a   Soddu, Silvia ^a   D'Orazi, Gabriella ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Antineoplastic drug; Apoptosis; Cisplatin; HIPK2; Kinase inhibitor SB203580; p53; p53 phosphorylation; RNAi; Serine threonine kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CISPLATIN; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EMBRYO; ENZYME ACTIVITY; ENZYME INDUCTION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TRANSCRIPTION INITIATION;

EID: 0345830383     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2003.09.032     Document Type: Article

References (41)

1. Kim Y.H., Choi C.Y., Lee S., Conti M.A., Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J. Biol. Chem. 273:1998;875-879.
2. Pierantoni G.M., Bulfone A., Pentimalli F., Fedele M., Iuliano R., Santoro M., Chiariotti L., Ballabio A., Fusco A. The homeodomain-interacting protein 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. Biochem. Biophys. Res. Commun. 290:2002;942-947.
3. Kim Y.H., Choi Y., Kim Y. Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1. Proc. Natl. Acad. Sci. 96:1999;350-355.
4. Choi Y.C., Kim Y.H., Kwon H.J., Kim Y. The homeodomain protein NK-3 recruits Groucho and a histone deacetylase complex to repress transcription. J. Biol. Chem. 274:1999;194-197.
5. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., Soddu S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser46 and mediates apoptosis. Nat. Cell Biol. 4:2002;11-19.
6. Hofmann T.G., Moller A., Sirma H., Zentgraf H., Taya Y., Droge W., Will H., Schmitz M.L. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4:2002;1-10.
7. Giaccia A.J., Kastan L.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12:1998;2973-2983.
8. Agarwal M.L., Taylor W.R., Chernov M.V., Chernova O.B., Stark G.R. The p54 network. J. Biol. Chem. 273:1998;1-4.
9. Vogt Sionov R., Haupt Y. The cellular response to p53: the decision between life and death. Oncogene. 18:1999;6145-6157.
10. Appella E., Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2001;2764-2772.
11. Bulavin D.V., Saito S., Hollander M.C., Sakaguchi K., Anderson C.W., Appella E., Fornace A.J. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18:1999;6845-6854.
12. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., Taya Y. P53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46- phosphorylated p53. Cell. 102:2000;849-862.
13. Drummond J., Anthoney A., Brown R., Mordich P. Cisplatin and adriamycin resistance are associated with MutL-alpha and mismatch repair deficiency in an ovarian cancer cell line. J. Biol. Chem. 271:1996;19645-19648.
14. Fink D., Zheng H., Nebel S., Norris P.S., Aebi S., Lin T.P., Nehme A., Christen R.D., Haas M., MacLeod C.L., Howell S.B. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 57:1997;1841-1845.
15. Zhang J.Y. Apoptosis-based anticancer drugs. Nat. Rev., Drug Discov. 2:2002;101-102.
16. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
17. Herr I., Debatin K.-M. Cellular stress response and apoptosis in cancer therapy. Blood. 98:2001;2603-2614.
18. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotides RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498.
19. Paddison P.J., Caudy A.A., Hannon G.J. Stable suppression of gene expression in mammalian cells by RNAi. Proc. Natl. Acad. Sci. U. S. A. 99:2002;1443-1448.
20. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 5567:2002;550-553.
21. Chen C., Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:1987;2752-2754.
22. Miyashita T., Reed J.C. The tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
23. Polyak K., Xia Y., Zweir J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature. 389:1997;300-305.
24. Manni I., Mazzaro G., Gurtner A., Mantovani R., Haugwitz U., Krause K., Engeland K., Sacchi A., Soddu S., Piaggio G. NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J. Biol. Chem. 276:2001;5570-5576.
25. Cummings J., Smyth J.F. DNA topoisomerase I and II as targets for rational design of new anticancer drug. Ann. Oncol. 4:1993;533-543.
26. Lippert B. Cisplatin: Chemistry and Biochemistry of a Leading Anti-cancer Drug. 1999;Wiley, New York.
27. Kazuyasu S., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:1998;2831-2841.
28. Hofmann T.G., Mincheva A., Lichter P., Droge W., Schmitz M.L. Human homeodomain-interacting protein kinase-2 (HIPK2) is a member of the DYRK family of protein kinase and maps to chromosome 7q32-q34. Biochimie. 82:2000;1123-1127.
29. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:1998;2831-2841.
30. Siliciano J.D., Canman C.E., Taya Y., Sakaguchi K., Appella E., Kastan M.B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:1997;3471-3481.
31. Sanchez-Prieto R., Rojas J.M., Taya Y., Gudkind J.S. A role for p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res. 60:2000;2464-2472.
32. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334.
33. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 95:1998;5-8.
34. Kim E.-J., Park J.-S., Um S.-J. Identification and characterization of HIPK2 interacting with p73 and modulating functions of p53 family in vivo. J. Biol. Chem. 277:2002;32020-32028.
35. Trost M., Kochs G., Haller O. Characterization of a novel serine/threonine kinase associated with nuclear bodies. J. Biol. Chem. 275:2000;7373-7377.
36. Wang Y., Hofmann T.G., Runkel L., Haaf T., Schaller H., Debatin K., Hug H. Isolation and characterization of cDNAs for the protein kinase HIPK2. Biochim. Biophys. Acta. 1518:2001;168-172.
37. Matsuo R., Ochiai W., Nakashima K., Taga T. A new expression cloning strategy for isolation of substrate-specific kinases by using phosphorylation site-specific antibody. J. Immunol. Methods. 247:2001;141-151.
38. Pierantoni G.M., Fedele M., Pentimalli F., Benvenuto G., Pero R., Biglietto G., Sanyoto M., Chiaritoti L., Fusco A. High mobility group I (Y) proteins bind HIPK2, a serine-threonone kinase protein which inhibits cell growth. Oncogene. 20:2001;6132-6141.
39. Flores E.R., Tsal K.Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 416:2002;560-564.
40. Strano S., Fontemaggi G., Costanzo A., Rizzo M.G., Monti O., Baccarini A., Del Sal G., Levrero M., Sacchi A., Oren M., Blandino G. Physical interaction with human tumor derived p53 mutants inhibits p63 activities. J. Biol. Chem. 277:2002;18817-188126.
41. Strano S., Blandino G. p73-mediated chemosensitivity. Cell Cycle. 2:2003;A34-A35.